Cardiac ArrestNCT06405581
The Impact of Frailty on Cardiopulmonary Resuscitation Adverse Outcomes in Patients Requiring Code Blue Activation
An observational study of Cardiac Arrest and Frailty, run by Umraniye Education and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study was to determine the independent association of frailty with cardiopulmonary resuscitation and predictive factors in patients triggering code blue response Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Cardiac Arrest, Frailty, Respiratory Arrest
- What is being tested?
- Edmonton frailty scale calculation
- How many people
- 2 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Dec 2025to 30 May 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- Adult, Older adult
Study population: Adult patients with hospitalization and those who are not inpatients (in the outpatient clinic system) requiring Code Blue will be included in the study.
Who may be able to join
- pediatric patients
Who cannot join
- pregnant patients
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Umraniye Education and Research Hospital
Istanbul, Umraniye, 34734
About this study
The aim of this study was to determine the independent association of frailty with cardiopulmonary resuscitation and predictive factors in patients triggering code blue response
Read the detailed description
Out-of-hospital cardiac arrest remains an important cause of death in developed countries with an average adult survival rate of 5.6% . In contrast, in-hospital cardiac arrests have been reported to have a survival rate between 4.1% and 40% and several factors have been shown to affect survival rates. These factors include patient and physiologic factors such as age, initial rhythm disturbance and duration of cardiopulmonary resuscitation (CPR), as well as hospital and logistic factors such as location and timing of the arrest.Code blue (CC) is the emergency call and management systems for respiratory or cardiac arrest. CC is used worldwide for the same emergency and the same color. The CC is the organization that initiates certain systems to initiate, perform and terminate the intervention of the designated responsible team. CC is given by a doctor (emergency, anesthesia and reanimation, internal medicine, pediatrics, intensive care specialist), anesthesia technician, nurse. The CC team is a team that prevents clinical death quickly, effectively and safely to provide life-saving support to patients. The CC team provides immediate intervention to patients, their relatives and all hospital staff. While the prevalence of frailty is 10-25% in the elderly aged 65 years and over, it increases to 30-45% in those aged 85 years and over. There are no definitive data on the prevalence of frail elderly in Turkey. The definition of frail elderly syndrome emerged as a concept in geriatrics and gerontology in the 1980s in response to the growing need for a unifying diagnosis among seemingly disparate and nonspecific disease presentations in older adults. The main symptoms are weight loss, weakness, fatigue and immobility, while the main findings are sarcopenia, osteopenia, malnutrition, impaired balance and gait, and slow walking. The importance of the definition of frailty comes from the fact that it is an alarm table used to indicate the susceptibility of the elderly to conditions such as clinical deterioration, falls and mortality over time. Frailty is a syndrome that can be prevented or at least postponed if diagnosed at an early stage. In fact, the frail elderly constitute a group vulnerable to adverse events with poor prognosis Mortality and complication rates are higher in elderly surgical patients than in younger surgical patients. Surgical risk is even higher in frail elderly patients. Regardless of the type of surgery and whatever assessment tool is used, the presence of frailty is associated with an approximately two- to threefold increased risk of adverse surgical outcome. Numerous studies have shown that frailty is a risk factor for postoperative complications, longer hospital stay and loss of functional independence at discharge. Therefore, identifying older patients with frailty offers opportunities to provide improved risk stratification and targeted interventions to improve outcomes The Edmonton Frailty Scale, a performance-based multidimensional frailty assessment tool, was designed by non-geriatricians in the west to help assess and screen frail older patients in primary care and at the bedside. It consists of 11 questions relating to nine different domains such as awareness, social support, mood, nutrition and functional performance. The result correlates well with the clinical impression of geriatricians through detailed history and physical examination.
- Conditions
- Cardiac Arrest, Frailty, Respiratory Arrest
- Being tested
- Edmonton frailty scale calculation
- Medical subject headings
- Heart Arrest, Frailty, Apnea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Edmonton frailty scale calculationOther
The frailty status of the patients will be assessed using the Edmonton frailty scale.
According to the Edmonton frailty scale;
- (0-5): not frail
- (6-7): sensitive
- (8-9): slightly fragile
- (10-11): moderately fragile,
- (12-17): extremely fragile
| Study group | Role | What they receive |
|---|---|---|
| Edmonton frailty scale ≥ 7 | The frailty status of the patients will be assessed using the Edmonton frailty scale.
According to the Edmonton frailty scale;
* (0-5): not frail
* (6-7): sensitive
* (8-9): slightly fragile
* (10-11): moderately fragile,
* (12-17): extremely fragile Receives: Other: Edmonton frailty scale calculation | |
| Edmonton frailty scale below 7 | The frailty status of the patients will be assessed using the Edmonton frailty scale.
According to the Edmonton frailty scale;
* (0-5): not frail
* (6-7): sensitive
* (8-9): slightly fragile
* (10-11): moderately fragile,
* (12-17): extremely fragile Receives: Other: Edmonton frailty scale calculation |
What is being measured
The primary outcome is the main question the study is designed to answer.
code blue reason
comorbid disease and dog usage
Measured: years
duration of CPR time
between the time of giving the blue code and the end of CPR
Measured: hours
Secondary outcomes (2)
the airway equipment used
intubation, supraglottic airway devices, tracheostomy, cricothyroidectomy, fiberbronchoscopy
Measured: days
mortality and morbidity
presence and duration of intensive care unit stay
Measured: mounts
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2024
- Study start1 Dec 2025
- Primary completion30 Apr 2026
- Study completion30 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac ArrestStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2 participants (actual)
Sponsor and investigators
- Lead sponsor
- Umraniye Education and Research Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Zeliha Alicikus, Umraniye Education and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06405581
- Sponsor's protocol ID
- UERH-AR-ZT-05
- Status last verified
- Oct 2026
- First submitted
- 29 Dec 2023
- Last updated
- 8 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Frailty on Cardiopulmonary Resuscitation Adverse Outcomes in Patients Requiring Code Blue Activation
- ClinicalTrials.gov ID
- NCT06405581
- Acronym / sponsor ID
- UERH-AR-ZT-05
- Conditions
- Cardiac Arrest, Frailty, Respiratory Arrest
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2 participants (actual)
- Lead sponsor
- Umraniye Education and Research HospitalOther government
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- 30 Apr 2026 (actual)
- Study completion
- 30 May 2026 (actual)
- First posted
- 8 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to determine the independent association of frailty with cardiopulmonary resuscitation and predictive factors in patients triggering code blue response
Detailed description
Out-of-hospital cardiac arrest remains an important cause of death in developed countries with an average adult survival rate of 5.6% . In contrast, in-hospital cardiac arrests have been reported to have a survival rate between 4.1% and 40% and several factors have been shown to affect survival rates. These factors include patient and physiologic factors such as age, initial rhythm disturbance and duration of cardiopulmonary resuscitation (CPR), as well as hospital and logistic factors such as location and timing of the arrest.Code blue (CC) is the emergency call and management systems for respiratory or cardiac arrest. CC is used worldwide for the same emergency and the same color. The CC is the organization that initiates certain systems to initiate, perform and terminate the intervention of the designated responsible team. CC is given by a doctor (emergency, anesthesia and reanimation, internal medicine, pediatrics, intensive care specialist), anesthesia technician, nurse. The CC team is a team that prevents clinical death quickly, effectively and safely to provide life-saving support to patients. The CC team provides immediate intervention to patients, their relatives and all hospital staff. While the prevalence of frailty is 10-25% in the elderly aged 65 years and over, it increases to 30-45% in those aged 85 years and over. There are no definitive data on the prevalence of frail elderly in Turkey. The definition of frail elderly syndrome emerged as a concept in geriatrics and gerontology in the 1980s in response to the growing need for a unifying diagnosis among seemingly disparate and nonspecific disease presentations in older adults. The main symptoms are weight loss, weakness, fatigue and immobility, while the main findings are sarcopenia, osteopenia, malnutrition, impaired balance and gait, and slow walking. The importance of the definition of frailty comes from the fact that it is an alarm table used to indicate the susceptibility of the elderly to conditions such as clinical deterioration, falls and mortality over time. Frailty is a syndrome that can be prevented or at least postponed if diagnosed at an early stage. In fact, the frail elderly constitute a group vulnerable to adverse events with poor prognosis Mortality and complication rates are higher in elderly surgical patients than in younger surgical patients. Surgical risk is even higher in frail elderly patients. Regardless of the type of surgery and whatever assessment tool is used, the presence of frailty is associated with an approximately two- to threefold increased risk of adverse surgical outcome. Numerous studies have shown that frailty is a risk factor for postoperative complications, longer hospital stay and loss of functional independence at discharge. Therefore, identifying older patients with frailty offers opportunities to provide improved risk stratification and targeted interventions to improve outcomes The Edmonton Frailty Scale, a performance-based multidimensional frailty assessment tool, was designed by non-geriatricians in the west to help assess and screen frail older patients in primary care and at the bedside. It consists of 11 questions relating to nine different domains such as awareness, social support, mood, nutrition and functional performance. The result correlates well with the clinical impression of geriatricians through detailed history and physical examination.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Edmonton frailty scale ≥ 7 | – | Other: Edmonton frailty scale calculationThe frailty status of the patients will be assessed using the Edmonton frailty scale. According to the Edmonton frailty scale; * (0-5): not frail * (6-7): sensitive * (8-9): slightly fragile * (10-11): moderately fragile, * (12-17): extremely fragile |
| Edmonton frailty scale below 7 | – | Other: Edmonton frailty scale calculationThe frailty status of the patients will be assessed using the Edmonton frailty scale. According to the Edmonton frailty scale; * (0-5): not frail * (6-7): sensitive * (8-9): slightly fragile * (10-11): moderately fragile, * (12-17): extremely fragile |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Adult patients with hospitalization and those who are not inpatients (in the outpatient clinic system) requiring Code Blue will be included in the study.
Key inclusion criteria (1 listed)
- pediatric patients
Key exclusion criteria (1 listed)
- pregnant patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Edmonton frailty scale calculationThe frailty status of the patients will be assessed using the Edmonton frailty scale. According to the Edmonton frailty scale; * (0-5): not frail * (6-7): sensitive * (8-9): slightly fragile * (10-11): moderately fragile, * (12-17): extremely fragile | Other | Edmonton frailty scale below 7, Edmonton frailty scale ≥ 7 |
Primary outcome
code blue reason
Time frame: years
comorbid disease and dog usage
duration of CPR time
Time frame: hours
between the time of giving the blue code and the end of CPR
2 secondary outcomes
the airway equipment used
Time frame: days
mortality and morbidity
Time frame: mounts
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Cardiac Arrest
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruitingObservational study
CAROTID DOPPLER AND CEREBRAL OXIMERY IN POST CARDIAC ARREST ICU PATIENTS
Cardiac Arrest (CA), Carotid Doppler
Active, not recruitingPhase 3
The Danish Out-of-Hospital Cardiac Arrest Study
Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome
RecruitingObservational study
Evaluation of Acid-base Disorders and Ventilation Settings in Cardiogenic Shock and Post-cardiac Arrest Patients: Comparison With VentilO Algorithm
Cardiac Arrest (CA), Cardiogenic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiac Arrest and Frailty, run by Umraniye Education and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
code blue reason (time frame: years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2026.